The Upheaval in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) – Chris Sweeney & Mary-Ellen Taplin

Chris Sweeney, MD and Mary-Ellen Taplin, MD discuss their current approach to treating patients with metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Sweeney first evaluates whether or not the patient is fit for chemotherapy and what their access is to abiraterone which both have a clear benefit in high volume disease. Based on the CHAARTED data, Dr. Taplin does not offer chemotherapy…

Read the full article here

Related Articles